<DOC>
	<DOCNO>NCT00040846</DOCNO>
	<brief_summary>This phase II trial study side effect best dose alemtuzumab give together fludarabine phosphate low-dose total body irradiation ( TBI ) well work donor stem cell transplant treat patient hematological malignancy . Giving chemotherapy low-dose TBI donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . Also , monoclonal antibody , alemtuzumab , find cancer cell either kill deliver cancer-killing substance without harm normal cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine ( CSP ) mycophenolate mofetil ( MMF ) transplant may stop happening .</brief_summary>
	<brief_title>Alemtuzumab , Fludarabine Phosphate , Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation Treating Patients With Hematological Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether stable allogeneic engraftment relate unrelated human leukocyte antigen ( HLA ) -mismatched stem cell donor safely establish use non-myeloablative conditioning regimen plus escalate dos anti-CD52 monoclonal antibody ( mAb ) Campath ( alemtuzumab ) patient hematologic malignancy . SECONDARY OBJECTIVES : I . Evaluate risk occurrence acute chronic graft-vs-host disease ( GVHD ) . II . Evaluate risk/incidence infection . III . Determine whether engraftment maintain single dose fludarabine , donor lymphocyte infusion ( DLI ) continue MMF/CSP . IV . Evaluate risk disease progression relapse . OUTLINE : This dose-escalation study alemtuzumab . CONDITIONING REGIMEN : Patients receive alemtuzumab intravenously ( IV ) 2 hour day -8 -5 fludarabine phosphate IV day -4 -2 . Patients also undergo low-dose TBI day 0 . HEMATOPOIETIC STEM CELL TRANSPLANTATION ( HSCT ) : Patients undergo allogeneic peripheral blood stem cell transplantation day 0 . IMMUNOSUPPRESSION : Patients receive CSP IV orally ( PO ) twice daily ( BID ) day -3 180 taper day 365 MMF PO thrice daily ( TID ) day 0-100 taper day 156 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must eligible conventional transplant must disease expect stable least 100 day without chemotherapy ; patient hematologic malignancy treatable hematopoietic stem cell transplant ( HSCT ) B cell malignancy except treatable autologous transplant include Aggressive nonHodgkin lymphoma ( NHLs ) Other Histologies Such Diffuse large B cell NHL Patients primary refractory relapse disease eligible autologous transplant Patients eligible follow autologous transplant remission relapse Planned tandem transplant allow patient high risk relapse Low grade NHL &lt; 6 month duration complete remission ( CR ) course conventional therapy Mantle Cell NHL may treat first CR Chronic lymphocytic leukemia ( CLL ) Must fail 2 line conventional therapy refractory fludarabine Hodgkin disease ( HD ) Must receive failed frontline therapy ; patient must prior autologous transplant eligible autologous transplant ; plan tandem transplant allow patient high risk relapse Multiple myeloma ( MM ) Must receive prior chemotherapy prior autologous transplant , unless autologous transplant possible ; plan tandem transplant allow patient high risk relapse Acute myeloid leukemia ( AML ) Must &lt; 5 % marrow blast time transplant Acute lymphocytic leukemia ( ALL ) Must &lt; 5 % blast time transplant Chronic myeloid leukemia ( CML ) Patients accept beyond chronic phase 1 ( CP1 ) receive previous myelosuppressive chemotherapy HSCT , &lt; 5 % marrow blast time transplant Myelodysplastic ( MDS ) /Myeloproliferative disorder Must fail previous myelosuppressive chemotherapy HSCT , &lt; 5 % marrow blast time transplant Waldenstrom 's Macroglobulinemia Must fail 2 course therapy Patients &lt; 12 year old must approve Fred Hutchinson Cancer Research Center ( FHCRC ) principal investigator ( PI ) Patients refuse treat conventional transplant protocol ; inclusion , criteria transplant must approve participate institutionÂ´s patient review committee Patient Care Conference ( PCC ) FHCRC FHCRC principal investigator Patients related unrelated donor The best available match HLA class II DRB1 DQB1 match donor incompatible single serologically detectable class I HLAA , B , C mismatch ; one additional allele level class I mismatch allow OR combination 2 allele level mismatch ( typed molecular level ) There likelihood rapid disease progression HLA type result preliminary search donor pool suggest 10/10 HLAA , B , C , DRB1 DQB1 match unrelated donor find There HLAA , B C one locus allelic mismatch related donor available There indication autologous transplantation treatment option DONOR : Related unrelated donor match HLADRB1 DQB1 allele ( must define high resolution type ) , mismatch : Any single serologically detectable HLAA B C antigen +/ 1 allele Any combination two HLAA , B , C alleles ( prospectively type molecular level ) Patients homozygous mismatched major histocompatibility complex ( MHC ) class I locus A positive crossmatch exists donor recipient Patients rapidly progressive intermediate high grade NHL Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient AML , ALL CML Life expectancy severely limited disease malignancy Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Fertile men woman unwilling use contraceptive 12 month post treatment Female patient pregnant breastfeed Human immunodeficiency virus ( HIV ) positive patient Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Patients active bacterial fungal infection unresponsive medical therapy Patients follow organ dysfunction symptomatic coronary artery disease ejection fraction &lt; 35 % cardiac failure require therapy ; ejection fraction require patient &gt; 50 year age , history cardiac disease anthracycline exposure Diffusion capacity carbon monoxide ( DLCO ) &lt; 35 % ; total lung capacity ( TLC ) &lt; 35 % ; force expiratory volume one second ( FEV1 ) &lt; 35 % and/or receive supplementary continuous oxygen Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude find fulminant liver failure ; cirrhosis liver evidence portal hypertension ; alcoholic hepatitis ; esophageal varix ; history bleed esophageal varix ; hepatic encephalopathy ; uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time ; ascites related portal hypertension ; bacterial fungal liver abscess ; biliary obstruction ; chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL ; symptomatic biliary disease Patients poorly control hypertension multiple antihypertensives Karnofsky score &lt; 70 adult patient LanskyPlay Performance Score &lt; 50 pediatric patient DONOR : Bone marrow ( BM ) donor DONOR : Donors HIVpositive and/or , medical condition would result increase risk granulocyte colonystimulating factor ( GCSF ) mobilization harvest peripheral blood stem cell ( PBSC ) DONOR : Donors &lt; 12 year age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>